Proceedings of 26th Annual Technological Advances in Science, Medicine and Engineering Conference 2022

Validating the safety and pharmacological profile of American Skullcap (Scutellaria lateriflora) in a bovine animal model
Manal Buabeid, Muralikrishnan Dhanasekaren
Abstract
Farm animals (chickens, goat/sheep, cattle, or pigs) are valuable and unique animal models. These animals provide an exceptional physiological and/or pathological in vivo/ ex vivo model for research investigations correlated to human wellbeing or ailments. These farm household animals serve as multi-role animal models that promote both pastoral/agronomic and biomedical exploration. Numerous studies have shown that the physiological functioning of the human organ system is more strongly linked to the physiology of farm animals than to rodents. Ultimately, the human genome sequence is more like the genome sequences of farm animals (cattle and pigs) compared to rodents. Therefore, cattle and pigs may be superior animal models to validate the safety and pharmacological profile of natural products and synthetic compounds. American Skullcap (Scutellaria lateriflora) is a traditionally used herb and has shown to be beneficial to reduce symptoms associated with hysteria, anxiety, epilepsy, chorea, and other psychological disorders. There are relatively very limited research studies that have been performed to measure the pharmacological activities of S. lateriflora extract (SLE). The purpose of this study was to determine the immunomodulatory and anti-inflammatory properties of SLE. Experiments were designed to measure the effects of an alcoholic extract of S. lateriflora (SLE) on inflammatory cyclooxygenase-1(COX-1), cyclooxygenase-2 (COX-2), 15-LOX (15 Lipoxygenases) enzyme activities, immunomodulating T lymphocytes activation and major histocompatibility complex class-II (MHC-II) expression in bovine monocyte-derived dendritic cells (MoDCs). The SLE inhibited inflammatory COX-1, COX-2, and 15 LOX activities but did not affect T cell proliferation, MHC-II expression on MoDCs, and pro-inflammatory cytokines production by T cells. Our results indicate anti-inflammatory activities of SLE and therefore is a potential treatment for various inflammation-driven diseases.

Last modified: 2022-08-20
Building: TASME Center
Room: Technology Hall
Date: August 28, 2022 - 12:05 PM – 12:20 PM

<< Back to Proceedings